Tesamorelin 10mg vial

GHRH analogue

What is Tesamorelin?

Last updated: 29 October 2026

A stabilised analogue of full-length growth-hormone-releasing hormone, studied in growth-hormone axis research.

GHRH analogueClinically studied
Class
GHRH analogue
Also known as
TH9507
Type
44-amino-acid modified peptide
Research stage
Clinically studied

01 · Classification

What it is

Tesamorelin is the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoyl group added at the start. That change protects it from rapid breakdown by enzymes.

It has been used in clinical research on adipose-tissue distribution and on the growth-hormone / IGF-1 axis.

02 · Mechanisms

What has been studied

  • GHRH receptor: stimulates the pituitary to release growth hormone in its natural pulsatile pattern.
  • IGF-1: studies measure downstream changes in insulin-like growth factor 1.
  • Adipose tissue: researched for effects on visceral versus subcutaneous adipose depots.

03 · Evidence

Where the research is

Clinical trial data has been published. Pharmaceutical formulations are regulated medicines in some countries. Research-grade material is a laboratory reagent.

04 · Primary sources

Read the literature

Search the primary research record directly rather than relying on summaries, including this one.

Research use only

Supplied strictly for laboratory and educational research. Not a drug, not for human or veterinary use, and not evaluated by the FDA. This overview is not medical advice and gives no dosing or administration guidance.

← All research overviews